Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 413-416

  Hwang, Shelley J E ^a,c   Carlos, Giuliana ^a,c   Chou, Shaun ^b   Wakade, Deepal ^a,c   Carlino, Matteo S ^a,c,d   Fernandez Penas, Pablo ^a,c  

^a WESTMEAD HOSPITAL   (Australia)

^b Department of Pathology and Diagnostic Oncology ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

anti programmed cell death 1 antibody; bullous pemphigoid; cutaneous adverse event; immunotherapy; metastatic melanoma; pembrolizumab

Indexed keywords

ANTIHISTAMINIC AGENT; B RAF KINASE; BETAMETHASONE DIPROPIONATE; CLOBETASOL; DOXYCYCLINE; IPILIMUMAB; METHOTREXATE; METHYLPREDNISOLONE ACEPONATE; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; TRIAMCINOLONE ACETONIDE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

AGED; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HUMAN; IMMUNOFLUORESCENCE; LUNG TOXICITY; MALE; METASTATIC MELANOMA; NON MELANOMA SKIN CANCER; PAPULE; PNEUMONIA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN EXAMINATION; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; IMMUNOLOGY; MELANOMA; PATHOLOGY; SKIN TUMOR;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MELANOMA; PEMPHIGOID, BULLOUS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84962113288     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000260     Document Type: Article

References (17)

1. Marquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, Gonzalez-Cao M, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015; 3:267.
2. Wolchok JD, Chan TA. Cancer: antitumour immunity gets a boost. Nature 2014; 515:496-498.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
4. Hwang S, Carlos G, Wakade D, Byth K, Kong B, Chou S, et al. Cutaneous adverse events of anti-programmed cell death 1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74:455-461.
5. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015; 25:265-268.
6. Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015; 38:37-39.
7. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33:2092-2099.
8. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013; 31:391-399.
9. Ruocco E, Wolf R, Caccavale S, Brancaccio G, Ruocco V, Lo Schiavo A. Bullous pemphigoid: associations and management guidelines: facts and controversies. Clin Dermatol 2013; 31:400-412.
10. Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015; 135:1445-1447.
11. Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Penas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol 2015; 172:239-243.
12. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167:1153-1160.
13. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014; 153:145-152.
14. Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2012; 25:129-137.
15. Kong B, Micklethwaite K, Swaminathan S, Kefford R, Carlino M. Autoimmune hemolytic anemia induced by anti-PD1 therapy in metastatic melanoma. Melanoma Res 2015; 26:202-204.
16. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2015; 22:886-894.
17. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-1682.